United Therapeutics (UTHR) Q4 2025: Tyvaso DPI Grows 24% as Pipeline Launches Set Up $4B Run Rate
UTHR’s fourth quarter showcased disciplined execution in pulmonary hypertension and IPF, with Tyvaso DPI, dry powder inhaler for PAH and PH-ILD, up 24% and a three-product launch wave positioned to accelerate growth beyond the $4 billion run rate by 2027. Management’s conviction in category-defining innovation, including the soft mist inhaler Tresmi and a once-daily superprostacyclin, signals a coming inflection in both revenue and competitive positioning. Investors should focus on near-term pivotal trial readouts and the durability of Tyvaso’s market leadership as new competitors emerge.
Summary
- Tyvaso DPI Momentum: Inhaled therapy platform gains share despite new entrants and seasonal headwinds.
- Pipeline Inflection: Three paradigm-shifting launches, including Tresmi and superprostacyclin, targeted for 2027.
- AI-Driven R&D: Digital lung modeling and transplant innovation broaden optionality beyond core PAH/IPF markets.
Performance Analysis
United Therapeutics delivered a robust quarter, with total revenue surpassing $3 billion for the first time on an annualized basis, driven by double-digit growth from Tyvaso and Orenitram, oral prostacyclin for PAH. The quarter’s 7% revenue growth was underpinned by Tyvaso’s 12% year-over-year gain, led by a standout 24% increase in Tyvaso DPI. This DPI growth is especially notable given the recent competitive entry from Liquidia, which initially sparked curiosity but ultimately failed to erode Tyvaso’s entrenched market position, as evidenced by referral rates rebounding to pre-competition levels in recent months.
Seasonality and weather disruptions weighed on Q4 patient starts, but management reported a pronounced February rebound, supporting their expectation for a return to sequential revenue growth by the second quarter. Operationally, the introduction of higher-dose DPI cartridges and combination kits has expanded dosing flexibility and improved patient convenience, enhancing Tyvaso DPI’s differentiation. Foundational therapies like Remodulin, parenteral prostacyclin, and Orenitram continue to anchor the commercial portfolio, with ongoing clinical data reinforcing their role in reducing mean pulmonary arterial pressure and supporting right ventricular function.
- Tyvaso DPI Referral Surge: Three of the last four months saw referral rates at or above pre-competitive launch levels.
- Product Mix Optimization: New high-dose cartridges streamline advanced dosing, supporting broader adoption.
- Seasonal Drag Offset: February patient starts rebounded after Q4 weather and distributor timing effects.
Overall, UTHR’s revenue base is increasingly anchored in differentiated inhaled therapies, with a clear pipeline-driven growth trajectory and operational resilience against competitive and seasonal volatility.
Executive Commentary
"This product is a revolutionary product proprietary drug device formulation of troprostanol into a soft mist inhaler. It will reduce the number one side effect of dry powder inhalers, which is coughing, by up to 90% based on the human studies we've done so far. And we intend to file for its approval in PAH and ILD this year and commercially launch it next year."
Dr. Martine Rothblatt, Chairperson & Chief Executive Officer
"2025 marked another year of record-breaking revenue, driven by double-digit percent revenue growth from Tyvaso and Orenitram, leading to 11% total revenue growth over a full year of 2024 and surpassing $3 billion in total revenue for the first time in our history."
Michael Bankiewicz, President & Chief Operating Officer
Strategic Positioning
1. Tyvaso DPI Platform Expansion
The Tyvaso DPI platform is the commercial and strategic core, with new high-dose cartridges and combination kits introduced to address advanced dosing needs in PAH and PH-ILD. These enhancements improve convenience and dosing flexibility, supporting broader adoption and longer-term growth. The device’s low inspiratory flow requirements and consistent delivery are key differentiators, especially as competitors struggle to match UT’s patient and prescriber retention.
2. Category-Crushing Pipeline Launches
Management is preparing for a triple wave of transformative launches in 2027: Tresmi, a soft mist inhaler that nearly eliminates cough; a once-daily superprostacyclin pill that addresses dosing frequency; and a new IPF therapy with superior efficacy to any prior FDA-approved drug. Each is positioned as a category-defining product, with regulatory filings targeted for this year and commercial launches next year or by mid-2027 for IPF.
3. AI-Enabled Drug Development
UTHR’s AI-enabled digital lung model is attracting partnership interest from major pharmaceutical companies, enabling hundreds of in silico phase three trial simulations and accelerating R&D cycles. This proprietary capability reduces both the cost and time to advance pulmonary therapies, creating a competitive moat and opening new business development avenues.
4. Transplantation Innovation
Transplantation R&D is advancing on multiple fronts, including xenotransplantation (Zeno), manufactured organs (Mural Matrix), and 3D bioprinting. With two patients already transplanted in the Zeno program and a full cohort expected by summer, UTHR is targeting a commercial xenotransplant product by 2030, expanding its addressable market and optionality well beyond pulmonary disease.
5. Stealth Clinical Development (Skunk Works)
The Skunk Works division is driving pipeline depth, with multiple stealth projects in once-daily inhalers, PRN (as-needed) inhalers, and further IPF/PAH assets. All are protected by long-duration intellectual property, reinforcing UTHR’s commitment to relentless innovation and future-proofing its portfolio.
Key Considerations
United Therapeutics’ quarter reflects a business at the intersection of operational discipline, product innovation, and strategic risk-taking. The following considerations are most relevant for investors tracking the company’s trajectory:
- Tyvaso DPI Defensibility: Despite competitive pressure from Liquidia, referral and retention trends indicate durable leadership, but continued vigilance on market share is warranted.
- Pipeline Execution Risk: The timing and outcome of pivotal trials (TETON1, superprostacyclin) will determine the pace and magnitude of the upcoming launch wave.
- R&D Productivity: The AI-enabled digital lung model provides a unique edge, but successful translation into new approvals and partnerships remains key.
- Transplant Portfolio Optionality: Early progress in xenotransplant and manufactured organs could unlock significant long-term value, though commercial timelines extend beyond the near-term revenue base.
- Revenue Growth Visibility: Management’s $4 billion run rate target is underpinned by current products, with new launches representing upside rather than a base case assumption.
Risks
Key risks include clinical trial setbacks, especially for the TETON1 IPF study and superprostacyclin, which could delay or diminish the impact of planned launches. Competitive threats from new inhaled therapies remain, particularly if rivals close the gap on delivery or efficacy. Regulatory delays, R&D execution risk, and long commercialization lead times in transplantation further complicate the growth narrative. Investors should also monitor payer dynamics and adoption curves for new delivery platforms.
Forward Outlook
For Q1 2026, United Therapeutics expects:
- Sequential revenue growth returning by Q2 as February patient starts rebound.
- Continued double-digit revenue growth for Tyvaso DPI and core PAH/PH-ILD franchise.
For full-year 2026, management reaffirmed:
- Double-digit revenue growth trajectory, independent of new launches.
- Progress toward a $4 billion run rate by the end of 2027, with additional upside from the three major pipeline launches.
Management underscored several drivers:
- Unblinding of pivotal trials (superprostacyclin, TETON1) in the coming months.
- Regulatory filings for Tresmi and other pipeline assets in 2026, with commercial launches targeted in 2027.
Takeaways
United Therapeutics is leveraging a robust existing portfolio and a pipeline of category-defining assets to drive both near-term revenue and long-term optionality.
- Tyvaso DPI’s resilience and platform enhancements position UTHR to defend and expand its leadership in PAH and PH-ILD, even as new entrants test the market.
- The 2027 launch wave, featuring Tresmi, a once-daily superprostacyclin, and a best-in-class IPF therapy, represents a material inflection point for both revenue and competitive positioning.
- Investors should watch pivotal trial readouts and the pace of regulatory filings, as these will determine the trajectory and magnitude of UTHR’s next growth phase.
Conclusion
United Therapeutics’ Q4 results reinforce its status as an innovation-driven specialty pharma with operational discipline and a clear line of sight to its next growth inflection. The company’s commitment to double-digit growth, pipeline launches, and digital R&D capabilities sets the stage for material upside, but execution on upcoming trials and launches will be decisive for valuation and market share.
Industry Read-Through
UTHR’s performance and pipeline strategy highlight the critical importance of device innovation and delivery optimization in specialty pharma, particularly in chronic pulmonary diseases where patient convenience and tolerability drive adoption. The company’s AI-driven R&D approach signals a broader industry shift toward digital modeling and simulation to de-risk late-stage development, a trend likely to accelerate across biotech. Transplantation advances and organ manufacturing efforts position UTHR as a bellwether for the convergence of regenerative medicine and pharma, with implications for both incumbents and new entrants targeting high-unmet-need markets.